Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Other Non-Current Assets (2016 - 2025)

Cytosorbents' Other Non-Current Assets history spans 15 years, with the latest figure at $1.5 million for Q4 2025.

  • Quarterly results put Other Non-Current Assets at $1.5 million for Q4 2025, up 2.56% from a year ago — trailing twelve months through Dec 2025 was $1.5 million (up 2.56% YoY), and the annual figure for FY2025 was $1.5 million, up 2.56%.
  • Other Non-Current Assets for Q4 2025 was $1.5 million at Cytosorbents, down from $3.6 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $6.5 million in Q2 2024 to a low of $1.5 million in Q4 2023.
  • The 5-year median for Other Non-Current Assets is $4.1 million (2023), against an average of $3.5 million.
  • The sharpest move saw Other Non-Current Assets skyrocketed 9082.55% in 2021, then plummeted 76.53% in 2025.
  • Year by year, Other Non-Current Assets stood at $5.0 million in 2021, then dropped by 10.51% to $4.4 million in 2022, then crashed by 66.56% to $1.5 million in 2023, then increased by 0.0% to $1.5 million in 2024, then grew by 2.56% to $1.5 million in 2025.
  • According to Business Quant data, Other Non-Current Assets over the past three periods came in at $1.5 million, $3.6 million, and $1.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.